PubRank

L Romani

Author PubWeight™ 84.83‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice. EMBO J 1995 3.48
2 Dendritic cells discriminate between yeasts and hyphae of the fungus Candida albicans. Implications for initiation of T helper cell immunity in vitro and in vivo. J Exp Med 2000 2.99
3 Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of Candida albicans. Eur J Immunol 1993 2.05
4 IL-22 defines a novel immune pathway of antifungal resistance. Mucosal Immunol 2010 1.76
5 A mannoprotein constituent of Candida albicans that elicits different levels of delayed-type hypersensitivity, cytokine production, and anticandidal protection in mice. Infect Immun 1994 1.68
6 Th1 and Th2 cytokines in mice with invasive aspergillosis. Infect Immun 1997 1.61
7 Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Blood 2001 1.60
8 Polymorphisms in toll-like receptor genes and susceptibility to pulmonary aspergillosis. J Infect Dis 2008 1.57
9 Role of L3T4+ lymphocytes in protective immunity to systemic Candida albicans infection in mice. Infect Immun 1989 1.56
10 T cell vaccination in mice with invasive pulmonary aspergillosis. J Immunol 2000 1.48
11 T helper cell type 1 (Th1)- and Th2-like responses are present in mice with gastric candidiasis but protective immunity is associated with Th1 development. J Infect Dis 1995 1.41
12 Interleukin 18 restores defective Th1 immunity to Candida albicans in caspase 1-deficient mice. Infect Immun 2000 1.39
13 Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis. J Infect Dis 1998 1.39
14 Endogenous interleukin 4 is required for development of protective CD4+ T helper type 1 cell responses to Candida albicans. J Exp Med 1998 1.37
15 T cell subsets and IFN-gamma production in resistance to systemic candidosis in immunized mice. J Immunol 1990 1.29
16 Antifungal type 1 responses are upregulated in IL-10-deficient mice. Microbes Infect 1999 1.27
17 Interleukin-4 and -10 exacerbate candidiasis in mice. Eur J Immunol 1995 1.27
18 Balancing inflammation and tolerance in vivo through dendritic cells by the commensal Candida albicans. Mucosal Immunol 2009 1.20
19 Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses. J Infect Dis 1999 1.19
20 Iron overload alters innate and T helper cell responses to Candida albicans in mice. J Infect Dis 1997 1.19
21 Cure of murine candidiasis by recombinant soluble interleukin-4 receptor. J Infect Dis 1994 1.19
22 CD4+ T-helper-cell responses in mice with low-level Candida albicans infection. Infect Immun 1996 1.18
23 NO-aspirin protects from T cell-mediated liver injury by inhibiting caspase-dependent processing of Th1-like cytokines. Gastroenterology 2000 1.13
24 Dynamics of extracellular release of Aspergillus fumigatus DNA and galactomannan during growth in blood and serum. J Med Microbiol 2009 1.13
25 A TH1-TH2-like switch in candidiasis: new perspectives for therapy. Trends Microbiol 1995 1.12
26 IFN-gamma is required for IL-12 responsiveness in mice with Candida albicans infection. J Immunol 1998 1.12
27 Immunity to fungi: editorial overview. Res Immunol 1998 1.12
28 IL-10 is required for development of protective Th1 responses in IL-12-deficient mice upon Candida albicans infection. J Immunol 1998 1.09
29 Defective co-stimulation and impaired Th1 development in tumor necrosis factor/lymphotoxin-alpha double-deficient mice infected with Candida albicans. Int Immunol 1998 1.07
30 The contribution of PARs to inflammation and immunity to fungi. Mucosal Immunol 2008 1.06
31 Impaired antifungal effector activity but not inflammatory cell recruitment in interleukin-6-deficient mice with invasive pulmonary aspergillosis. J Infect Dis 2001 1.06
32 Impaired generation of bone marrow B lymphocytes in mice deficient in C/EBPbeta. Blood 1997 1.06
33 Chronic granulomatous disease. Cell Mol Life Sci 2009 1.05
34 Antibody and/or cell-mediated immunity, protective mechanisms in fungal disease: an ongoing dilemma or an unnecessary dispute? Med Mycol 1998 1.04
35 A 70-kilodalton recombinant heat shock protein of Candida albicans is highly immunogenic and enhances systemic murine candidiasis. Infect Immun 1998 1.04
36 Intranasally delivered siRNA targeting PI3K/Akt/mTOR inflammatory pathways protects from aspergillosis. Mucosal Immunol 2009 1.03
37 TGF-beta is important in determining the in vivo patterns of susceptibility or resistance in mice infected with Candida albicans. J Immunol 1995 1.03
38 Anti-Candida resistance in the mouse brain and effect of intracerebral administration of interleukin 1. J Gen Microbiol 1991 0.97
39 Induction of protective Th1 responses to Candida albicans by antifungal therapy alone or in combination with an interleukin-4 antagonist. J Infect Dis 1997 0.95
40 Mucosal and systemic T helper cell function after intragastric colonization of adult mice with Candida albicans. J Infect Dis 1993 0.94
41 Specific and non-specific immunity to Candida albicans: a lesson from genetically modified animals. Res Immunol 1998 0.93
42 Defective antifungal T-helper 1 (TH1) immunity in a murine model of allogeneic T-cell-depleted bone marrow transplantation and its restoration by treatment with TH2 cytokine antagonists. Blood 2001 0.93
43 The rs5743836 polymorphism in TLR9 confers a population-based increased risk of non-Hodgkin lymphoma. Genes Immun 2011 0.92
44 Cytokine- and T-helper-dependent immunity in murine aspergillosis. Res Immunol 1998 0.89
45 Prognostic significance of genetic variants in the IL-23/Th17 pathway for the outcome of T cell-depleted allogeneic stem cell transplantation. Bone Marrow Transplant 2010 0.88
46 Immunity to Aspergillus fumigatus: the basis for immunotherapy and vaccination. Med Mycol 2005 0.87
47 Cytokines in candidiasis and aspergillosis. Curr Pharm Biotechnol 2000 0.85
48 Knockout mice as experimental models of virulence. Med Mycol 2000 0.85
49 Raven's colored progressive matrices: a normative study of a random sample of healthy adults. Acta Neurol Scand 1993 0.84
50 Cytokines and mycoses. Med Mycol 1998 0.84
51 Electrochemotherapy treatment for bilateral pleomorphic rhabdomyosarcoma in a cat. J Small Anim Pract 2010 0.83
52 Intracerebral adoptive immunotherapy of a murine lymphoma antigenically altered by drug treatment in vivo. J Natl Cancer Inst 1982 0.82
53 Innate and adaptive immunity to Candida albicans: A new view of an old paradigm. Rev Iberoam Micol 1999 0.82
54 Low-dose streptozotocin-induced diabetes in mice. II. Susceptibility to Candida albicans infection correlates with the induction of a biased Th2-like antifungal response. Cell Immunol 1993 0.82
55 Host immune reactivity determines the efficacy of combination immunotherapy and antifungal chemotherapy in candidiasis. J Infect Dis 2000 0.81
56 Involvement of the Th1 subset of CD4+ T cells in acquired immunity to mouse infection with Trypanosoma equiperdum. Cell Immunol 1992 0.81
57 Early T cell unresponsiveness in mice with candidiasis and reversal by IL-2: effect on T helper cell development. J Immunol 1997 0.80
58 Induction and protection of autoimmune rheumatic diseases. The role of infections. Clin Exp Rheumatol 2008 0.80
59 Type 1 and type 2 cytokines: from basic science to fungal infections. Med Mycol 1998 0.80
60 Immunotherapy of aspergillosis. Clin Microbiol Infect 2011 0.79
61 Increase of natural killer activity of mouse lymphocytes following in vitro and in vivo treatment with lithium. Immunopharmacol Immunotoxicol 1988 0.79
62 [Epidemiological data and importance of constitutional, familial, nutritional and environmental factors in rheumatic fever]. G Mal Infett Parassit 1967 0.79
63 Intrasplenic immunization for the induction of humoral and cell-mediated immunity to nitrocellulose-bound antigen. J Immunol Methods 1991 0.79
64 Naming disorders and semantic representations. J Psycholinguist Res 1992 0.78
65 Drug-induced immunogenic changes of murine leukemia cells: dissociation of onset of resistance and emergence of novel immunogenicity. J Natl Cancer Inst 1983 0.78
66 Immunogenic changes of murine lymphoma cells following in vitro treatment with aryl-triazene derivatives. Cancer Immunol Immunother 1984 0.78
67 The plasticity of dendritic cells at the host/fungal interface. Immunobiology 2001 0.78
68 Delayed-type hypersensitivity to tumor antigens co-expressed with immunogenic determinants induced by xenogenization. Int J Cancer 1989 0.78
69 Search for class II major histocompatibility complex molecular involvement in the response of Lyt-2+ cytotoxic T lymphocyte precursors to alloantigen. Eur J Immunol 1985 0.78
70 Chemical xenogenization of experimental tumors. Cancer Metastasis Rev 1987 0.78
71 AhR: far more than an environmental sensor. Cell Cycle 2014 0.78
72 Antigenic properties of lymphoma sublines derived from a drug-treated immunogenic L5178Y leukemia. Transplantation 1978 0.77
73 Systemic adoptive immunotherapy of a highly immunogenic murine lymphoma growing in the brain. Int J Cancer 1983 0.77
74 Five years of experience in nocturnal enuresis and urinary incontinence in children: where we are and where we are going. Urol Int 2013 0.77
75 Antigenic changes related to drug action. Prog Clin Biol Res 1983 0.76
76 Induction of protective Th1 responses to Candida albicans by antifungal therapy alone or in combination with an interleukin-4 antagonist. J Chemother 1998 0.76
77 Cell-mediated immunity in the course of cervical ectropion. Clin Exp Obstet Gynecol 1994 0.76
78 Neutrophils producing interleukin-10 antagonize the effect of interleukin-12 in mice with candidiasis. Ann N Y Acad Sci 1996 0.75
79 In vitro generation of primary cytotoxic lymphocytes against L5178Y leukemia antigenically altered by 5-(3,3'-dimethyl-1-triazeno)-imidazole-4-carboxamide in vivo. Transplantation 1979 0.75
80 [Purulent meningitis in childhood]. G Mal Infett Parassit 1966 0.75
81 [Long term depression of the primary antibody response due to a single administration of 5-(3,3-dimethyl-1-triazeno)-imidazole-carboxamide (DTIC)]. Boll Soc Ital Biol Sper 1977 0.75
82 [Myasthenia gravis and pregnancy. Review of the literature and considerations on the immunoprotective effect of alpha-fetoprotein through the observation of a clinical case]. Ann Ostet Ginecol Med Perinat 1989 0.75
83 Generation of monoclonal antibodies to a chemically xenogenized murine lymphoma. Pharmacol Res Commun 1988 0.75
84 Lack of correlation between DNA-methylating activity and appearance of the immunogenic phenotype in clones of a murine lymphoma treated with mutagens. Cancer Immunol Immunother 1989 0.75
85 "In vitro" induction of primary cell-mediated immune response to drug-altered lymphoma cells. Boll Soc Ital Biol Sper 1978 0.75
86 Immunopharmacological studies of PTT.119, a new synthetic bis-(2-chloroethyl)amino-L-phenylalanine derivative. Immunopharmacol Immunotoxicol 1987 0.75
87 DNA methylating activity in murine lymphoma cells treated with xenogenizing chemicals. Cancer Detect Prev Suppl 1987 0.75
88 T-cell subsets, IFN-gamma production and efferent specificity in anti-parental tumor immunity induced by mouse sensitization with xenogenized variant cells. Int J Cancer 1990 0.75
89 Drugs and the immune system: the emerging era of immunopharmacology. Trends Immunol 2001 0.75
90 Changes in the tumorigenic and metastatic properties of murine melanoma cells treated with a triazene derivative. Clin Exp Metastasis 1989 0.75
91 Chemical xenogenization of murine lymphoma cells with triazene derivatives: immunotoxicological studies. Cancer Immunol Immunother 1984 0.75
92 [Transfer in vivo of cytotoxic immune lymphocytes obtained in vitro in primary culture against a murine lymphoma antigenically altered by DTIC]. Boll Soc Ital Biol Sper 1979 0.75
93 Expression of normal histocompatibility antigens in murine lymphomas treated with 5-(3,3'-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) in vivo. Eur J Cancer 1981 0.75
94 Drug-induced modulation of IL-2 production in experimental murine trypanosomiasis. Int J Immunopharmacol 1992 0.75
95 Immunopharmacological studies of ribavirin, a broad-spectrum antiviral agent. Chemioterapia 1987 0.75
96 [Secondary cytotoxic "in vitro" response: crossed antigenic response of murine lymphoma sublines treated with DTIC]. Boll Soc Ital Biol Sper 1977 0.75
97 [The complications of measles. Study of 881 cases treated in the Ospedale Pediatrico "Bambin Gesu" in Rome in the period 1960-64]. G Mal Infett Parassit 1967 0.75
98 Identification and immunogenic properties of an 80-kDa surface antigen on a drug-treated tumor variant: relationship to MuLV gp70. Eur J Immunol 1990 0.75
99 Drug-mediated changes of tumour cell immunogenicity and antigenicity. Int J Tissue React 1982 0.75
100 Untreated or drug-treated tumor cells are differentially recognized by allogeneic lymphocytes. Int J Immunopharmacol 1994 0.75
101 Inhibition of murine lymphoma growth by adoptive transfer of lymphocytes sensitized to a xenogenized tumor variant. Int J Cancer 1987 0.75
102 Immunogenic tumor variants induced by drug treatment of the L5178Y lymphoma: search for serologically defined antigens at the clonal level. Int J Cancer 1992 0.75
103 Preliminary analysis of effects of "normal" aging on different memory processes and abilities. Percept Mot Skills 1990 0.75
104 [Gingivopathy during pregnancy: salivary levels of IgG, IgA, IgM and lysozyme]. G Stomatol Ortognatodonzia 1984 0.75
105 [Zuelzer-Apt syndrome. Description of a case]. Pediatria (Napoli) 1968 0.75
106 DNA methylating activity in murine lymphoma cells xenogenized by triazene derivatives. Int J Cancer 1987 0.75
107 Cell-mediated immunity to chemically xenogenized tumors--III. Generation of monoclonal antibodies interfering with reactivity to novel antigens. Int J Immunopharmacol 1988 0.75
108 [In vitro cytolysis mediated by NK effectors: modification of the susceptibility of the target cell by in vivo treatment with DTIC]. Boll Soc Ital Biol Sper 1981 0.75
109 [Therapy of pertussis]. Minerva Pediatr 1973 0.75
110 Humoral response against murine lymphoma cells xenogenized by drug treatment in vivo. Int J Cancer 1985 0.75
111 Induction of tumor suppression and delayed-type footpad reaction by transfer of lymphocytes sensitized to a xenogenized tumor variant. Int J Cancer 1988 0.75
112 [Immunoglobulin treatment in the course of acute and subacute diseases of infectious etiology, of the respiratory and gastrointestinal tract in infants]. Minerva Pediatr 1972 0.75
113 Tumor-specific L3T4+ and Lyt-2+ lymphocytes in mice primed to mutagenized cell variants. Int J Immunopharmacol 1992 0.75
114 O6-methylguanine-DNA methyltransferase activity and induction of novel immunogenicity in murine tumor cells treated with methylating agents. Cancer Chemother Pharmacol 1992 0.75
115 Adoptive immunotherapy of intracerebral murine lymphomas: role of different lymphoid populations. Int J Cancer 1985 0.75
116 Susceptibility of murine lymphoma cells treated with 5-(3,3-dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide to NK-mediated cytotoxicity in vitro. Int J Immunopharmacol 1983 0.75
117 Changes of the immunogenic properties of K36 lymphoma treated in vivo with 5(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC). Eur J Cancer 1979 0.75
118 [Experimental models of immunochemotherapeutic synergism: study of the influence of the treatment schedule]. Boll Soc Ital Biol Sper 1979 0.75
119 Combined effects of immunity and antitumor drugs against cancer. I. In vivo studies with cis-diamminedichloroplatinum and cyclophosphamide in mouse models. Chemioterapia 1987 0.75
120 Antilymphoma graft responses in the mouse brain: a study of T-dependent functions. Int J Cancer 1983 0.75
121 [Clinico-morphological changes in ectropion after treatment with polydeoxyribonucleotide (PDRN)]. Ann Ostet Ginecol Med Perinat 1991 0.75
122 [Topical therapy with placental polydeoxyribonucleotide in cervical ectopy and ectropion]. Ann Ostet Ginecol Med Perinat 1989 0.75
123 [A case of benign recurrent Mollaret meningitis]. Pediatria (Napoli) 1968 0.75
124 Regulation of tumor antigen expression by drugs acting as mutagens and/or gene activators. Pharmacol Res Commun 1988 0.75
125 Appearance of strong transplantation antigens in non-immunogenic lymphoma following drug-treatment in vivo. J Immunopharmacol 1980 0.75